Mylan NV develops, licenses, manufactures, markets, and distributes generic, branded generic, and specialty pharmaceuticals worldwide. The company was founded in 1961 and is based in Potters Bar, Hertfordshire.
MYL Price Forecast Based on DCF Valuation
DCF Fair Value Target:
We started the process of determining a valid price forecast for Mylan NV with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Mylan NV ranked in the 60th percentile in terms of potential gain offered. More precisely, our analysis suggests the stock is undervalued by approximately 27.5% on a DCF basis. In terms of the factors that were most noteworthy in this DCF analysis for MYL, they are:
44% of the company's capital comes from equity, which is greater than only 18.26% of stocks in our cash flow based forecasting set.
Relative to other stocks in its sector (Healthcare), Mylan NV has a reliance on debt greater than 88.31% of them.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
Want more companies with a valuation profile/forecast similar to that of Mylan NV? See UNH, MEDP, AMED, MGLN, and DVA.